目的:在撒哈拉以南的非洲人中,γ谷氨酰转移酶(GGT)作为心血管风险(CVR)的生物标志物的有用性仍未被探索。评估其在非糖尿病性喀麦隆高血压患者CVR评估中的相关性。这是一项针对57.7±10岁的非糖尿病高血压成年人(62%为女性)的前瞻性横断面研究。没有急性或慢性肝病的证据,我们评估了GGT水平,并将其与经过验证的CVR生物标志物相关联,CVR评分(世卫组织风险评分,弗雷明汉2008、ASCVD2013、EuroSCORE2003和雷诺兹评分),和血浆动脉粥样硬化指数(PAI)。
结果:我们发现GGT和PAI在线性回归上呈正相关,但弱相关[0.004(0.001;0.007);p=0.021],这取决于甘油三酯水平(r=0.17;p=0.03)。我们没有发现GGT水平和CVR评分研究结果之间的显著关联;尽管与动脉粥样硬化风险有关,正如非撒哈拉以南非洲人的文献报道的那样,GTT对我们人口的CVR评估价值不大。
OBJECTIVE: The usefulness of gamma glutamyl transferase (GGT) as biomarker of cardiovascular risk (CVR) remains unexplored in sub-Saharan Africans. To evaluate their relevance on CVR assessment in non-diabetic hypertensive
Cameroonians. This was a prospective cross-sectional study on non-diabetic hypertensive adults aged 57.7 ± 10 years (62% female), without evidence of acute or chronic liver disease, in which we assessed GGT levels and correlates it with validated CVR biomarkers, CVR scores (WHO risk score, Framingham 2008, ASCVD 2013, EuroSCORE 2003, and Reynolds score), and plasma atherogenic index (PAI).
RESULTS: We found a positive but weak association between GGT and PAI on linear regression [0.004 (0.001; 0.007); p = 0.021], which was dependent of triglycerides levels (r = 0.17; p = 0.03). We did not find a significant association between GGT levels and the results of the CVR scores studied; Although being related to atherogenic risk, as reported in literature in non-sub-Saharan Africans, GGTs would be of little value for CVR assessment in our population.